Apixaban
| Price | $100 |
| Package | 25KG |
| Min. Order: | 1KG |
| Supply Ability: | 1000KG |
| Update Time: | 2019-07-06 |
Product Details
| Product Name: Apixaban | CAS No.: 503612-47-3 |
| EC-No.: 1308068-626-2 | Min. Order: 1KG |
| Purity: 98% | Supply Ability: 1000KG |
| Release date: 2019/07/06 |
CR076
| Apixaban Basic information |
| Indications and Usage Mechanisms of Action Clinical Research Drug Interactions Warnings and Precautions |
| Product Name: | Apixaban |
| Synonyms: | Apixaban;Apixaban, BMS 562247-01;1H-Pyrazolo[3,4-c]pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-;1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;BMS 562247-01;1-(4-Methoxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid aMide;1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4, 5-dihydropyrazolo[3,4-c]pyridine-3-carboxaMide;Nilotinib and its interMediate |
| CAS: | 503612-47-3 |
| MF: | C25H25N5O4 |
| MW: | 459.504 |
| EINECS: | 1308068-626-2 |
| Product Categories: | Inhibitor;Inhibitors |
| Mol File: | 503612-47-3.mol |
 |
|
| Apixaban Chemical Properties |
| density | 1.42 |
| Safety Information |
| MSDS Information |
| Apixaban Usage And Synthesis |
| Indications and Usage | Apixaban is a new form of oral anticoagulant drug developed by Bristol Myers Squibb and Pfizer. It is a new form of oral Xa factor inhibitor, and its commercial name is Eliquis. Apixaban is used to treat adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolism (VTE) |
| Mechanisms of Action | Apixaban is an oral selective activated Xa factor inhibitor and can prevent thrombin generation and thrombosis. |
| Clinical Research | Apixaban is the third new oral anticoagulant to go on sale, following dabigatran and rivaroxaban, and it has already been approved in Europe for preventing venous thromboembolism in patients undergoing elective hip or knee replacement surgery. Out of these three oral anticoagulants approved in Europe, compared to the current standard preventative treatment against venous thromboembolism, enoxaparin, rivaroxaban excelled in the record experiment, and apixaban excelled in the advance experiment. Rivaroxaban’s curative effects were slightly superior, but it caused more severe bleeding than apixaban. Researchers attributed these differences to medication time, as rivaroxaban was taken 6-8 hours after surgery in the record experiment, while apixaban was used 18 hours after surgery in the advance experiment. These drugs have better curative effect when used closer to time of surgery, but also have an increased bleeding risk. Clinical research showed that compared to a daily subdermal injection of 40mg enoxaparin, 2 oral 2.5mg dosages of apixaban had better preventative effects against venous thromboembolism following hip or knee replacement surgery and did not increase bleeding risk. |
| Drug Interactions | 1.A double inhibitor of strong CYP3A4 and P-gp increases apixaban’s blood levels: decrease Eliquis dosage to 2.5mg or avoid simultaneous usage. 2.A inductor of strong CYP3A4 and P-gp can decrease apixaban’s blood levels: avoid simultaneous usage. |
| Warnings and Precautions |
|
| Uses | Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. |
| Definition | ChEBI: A pyrazolopyridine that is 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide substituted at position 1 by a 4-methoxyphenyl group and at position 6 by a 4-(2-oxopiperidin-1-yl)phenyl group. It is used for the prevention and treatment of thromboembolic diseases. |
| References | https://en.wikipedia.org/wiki/Apixaban https://www.drugbank.ca/drugs/DB06605 |
| Apixaban Preparation Products And Raw materials |
Company Profile Introduction
Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals.
Mainly deals in the sales of:
Pharmaceutical intermediates
OLED intermediates：
Pharmaceutical intermediates;
OLED intermediates;
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $33.00/2mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-14 | |
| $10.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-11-06 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-09-05 | |
| $99.00/5kg |
VIP1Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2024-08-09 | |
| $0.00/1kg |
VIP1Y
|
Binzhou Lista Trading Limited
|
2024-07-26 | |
| $0.00/25kg |
VIP1Y
|
Hebei Mojin Biotechnology Co.,Ltd
|
2024-07-25 | |
| $0.00/1kg |
VIP1Y
|
Hangzhou Hyper Chemicals Limited
|
2024-07-03 | |
| $30.00/1box |
VIP1Y
|
Strong peptide cross-border e-commerce Co. LTD
|
2024-07-03 | |
| $0.00/1Kg/Bag |
VIP4Y
|
Sinoway Industrial co., ltd.
|
2024-06-27 | |
| $6.00/1kg |
VIP1Y
|
Hebei Longbang Technology Co., Ltd
|
2024-06-03 |
China- Since: 2014-12-17
- Address: No.967,15th Floor,Unit 7, Building 1, No.70 of DianChang Road, High-tech Development Zone, Zhengzho
INQUIRY
楊俊青
sales@coreychem.com
sales@coreychem.com